Tailored Risk Protocols Needed for Aesthetic Procedures in Allergic Skin Disease

As demand for cosmetic dermatology continues to grow, a new review published in Clinics in Dermatology offers a comprehensive framework for safely managing aesthetic interventions in a patient population that is often overlooked: those with underlying allergic and inflammatory skin diseases.¹

The authors highlighted that individuals with conditions such as chronic inducible urticaria (CIU), atopic dermatitis (AD), allergic contact dermatitis, and hereditary angioedema (HAE) face distinct and elevated risks when undergoing procedures like botulinum toxin injections, hyaluronic acid (HA) fillers, laser treatments, and microneedling.

“Despite the rising interest for cosmetic procedures in this patient demographic, there are limited safety data in aesthetic dermatology, and dermatologists often have to rely on extrapolated findings from the literature,” the authors explained. The new review explores the risks associated with aesthetic procedures in those with allergic and inflammatory skin conditions, as well as recommendations for assessment and preventive management prior to procedures.

Local Anesthetics: True Allergy Is Rarer Than Believed

One of the review's central messages concerns local anesthetics, where the authors suggest that most adverse reactions are misclassified as allergic. True immunoglobulin E (IgE)–mediated hypersensitivity accounts for fewer than 1% of reported reactions, with the majority stemming from vasovagal responses, pharmacologic toxicity, or reactions to preservatives like parabens.²

The investigators recommend that preventive strategies prioritize appropriate agent selection and injection technique over routine pharmacologic prophylaxis.¹ Specifically, they advise using the lowest effective concentration, favoring preservative-free amide formulations, and avoiding intravascular administration. Routine corticosteroid or antihistamine premedication is not indicated except in select patients with a documented history of urticarial or mast cell–mediated reactions.

Injectables and Hypersensitivity: Formulation Matters

For botulinum neurotoxin type A, hypersensitivity reactions—including urticaria-like presentations and painful nodule formation at injection sites—have been attributed to complex proteins or stabilizers, such as gelatin, present in some formulations. The authors noted that formulations without complexing proteins may be preferable in allergy-prone patients.

HA fillers, while generally well tolerated, can also trigger both early IgE-mediated reactions and delayed T cell–mediated responses, and the reason for these responses is multifactorial, the authors explained. Hyaluronidase, used to dissolve HA fillers, carries a notable concern: cross-reactivity with Hymenoptera venoms. Patients with a history of bee or wasp sting allergy should be carefully screened, and skin pretesting may be warranted when animal-derived formulations are used.

Condition-Specific Precautions for Aesthetic Procedures

For patients with CIU, aesthetic procedures can act as direct physical triggers due to needle trauma, thermal exposure from lasers, vibration from microdermabrasion, and postfiller massage, which all mimic the stimuli that precipitate wheals. The authors recommend second-generation H1 antihistamines beginning 3 days before the procedure and continuing for at least 3 days afterward, with postponement advised if the patient has had an active flare within the preceding 2 to 4 weeks.

In patients with AD, procedures should be deferred during active flares or periods of significant xerosis, the authors advised. Given increased susceptibility to herpes simplex virus, antiviral prophylaxis is warranted in patients with recurrent eczema herpeticum. The review also noted that dupilumab may reduce eczema herpeticum risk by approximately 70%.

Patients with HAE represent the highest-risk group, requiring short-term prophylaxis before any invasive cosmetic procedure. Intravenous plasma-derived C1 inhibitor administered at 1000 IU or 20 IU/kg as close to the procedure as possible is the preferred first-line option, the authors explained.

The authors concluded that aesthetic procedures can be safely performed across this patient population when individualized risk assessment, condition-specific prophylaxis, and appropriate procedural technique are applied. Routine pharmacologic premedication, they noted, is not a substitute for careful history-taking and trigger avoidance.

“By recognizing condition-specific risks, we can safely expand the range of aesthetic treatments available to this patient population,” the authors wrote.

References

1. Kömürcügil Yiğit İ, Türsen Ü, Türsen B, Solak B, Karstarlı Bakay ÖS, Kroumpouzos G. Aesthetic interventions in patients with allergic skin diseases: risk assessment and evidence-based preventive risk management. Clin Dermatol. Published online March 13, 2026. doi:10.1016/j.clindermatol.2026.03.001

2. Jiang S, Tang M. Allergy to Local Anesthetics is a Rarity: Review of Diagnostics and Strategies for Clinical Management. Clin Rev Allergy Immunol. 2023;64(2):193-205. doi:10.1007/s12016-022-08937-x